• KinATLAS
  • TranscriptoNET
  • PhosphoNET
  • OncoNET
  • KinaseNET
  • DrugKiNET
  • DrugProNET
  • KiNET-AM
  • Kinetica Online

Updated November 2019

Home | Kinexus | Contact | Credits

Nomenclature

Short Name:
KIT
Full Name:
Mast-stem cell growth factor receptor
Alias:
  • CD117
  • C-kit
  • SCFR
  • SL
  • V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene
  • V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue
  • EC 2.7.10.1
  • Kinase Kit
  • Mast/stem cell growth factor receptor precursor
  • PBT

Classification

Type:
Protein-tyrosine kinase
Group:
TK
Family:
PDGFR
SubFamily:
NA
 
 

Specific Links

Entrez-Gene Entry: 3815
Entrez-Protein Entry: NP_000213
GeneCards Entry: SCFR
KinBASE Entry: KIT
OMIM Entry: 164920
Pfam Entry: P10721
PhosphoNET Entry: P10721
Phosphosite Plus Entry: 588
Protein Data Bank Entry: 1PKG
ScanSite Entry: P10721
Source Entry: KIT
UCSD-Nature Entry: A001344
UniProt Entry: P10721
Kinexus Products: KIT
Mast/stem cell growth factor receptor protein-tyrosine Kit pan-specific antibody AB-NK241-1
Mast/stem cell growth factor receptor protein-tyrosine Kit pan-specific antibody AB-NK241-2
Mast/stem cell growth factor receptor protein-tyrosine Kit Y936 phosphosite-specific antibody AB-PK673
Mast/stem cell growth factor receptor protein-tyrosine Kit S821+Y823 phosphosite-specific antibody AB-PK674
Mast/stem cell growth factor receptor protein-tyrosine Kit (S38-D52, human) peptide - Powder PE-01AUS99
Mast/stem cell growth factor receptor protein-tyrosine Kit (S38-D52, human) peptide - Powder PE-01AUS99
Mast/stem cell growth factor receptor protein-tyrosine Kit (L119-L133, human) peptide - Powder PE-01AUT99
Mast/stem cell growth factor receptor protein-tyrosine Kit (L813-N819, human) peptide - Powder PE-01BFT99
Mast/stem cell growth factor receptor protein-tyrosine Kit (L813-N819, human) peptide - Powder PE-01BFU99
Mast/stem cell growth factor receptor protein-tyrosine Kit (N933-L939, human) pY936 phosphopeptide - Powder PE-04AGB95
Mast/stem cell growth factor receptor protein-tyrosine Kit (K818-G827, human) pS821+pY823 phosphopeptide - Powder PE-04ARM95
Mast/stem cell growth factor receptor protein-tyrosine Kit (N933-L939, human) pY936 phosphopeptide - Powder PE-04AZV00

General Links

ClustalW2
GPS-Cuckoo
Human Protein Atlas
Kinase.com
Kinase Research
Kinasource
Kinomer
Netphorest
NetworKIN
Phosida
PhosphoElm
Protein Blast
ScanSite
String

Structure

Mol. Mass (Da):
109,865
# Amino Acids:
976
# mRNA Isoforms:
3
mRNA Isoforms:
109,865 Da (976 AA; P10721); 109,451 Da (972 AA; P10721-2); 46,658 Da (413 AA; P10721-3)
4D Structure:
Interacts with APS. Interacts with MPDZ (via the tenth PDZ domain). Interacts with PTPRU.
1D Structure:
Retrieve Gene Sequence
Retrieve Full Protein Sequence
Retrieve Catalytic Domain Sequence
 
3D Image (rendered using PV Viewer):

PDB ID
1PKG

Subfamily Alignment
subfamily domain
 
Domain Distribution:
Start End Domain
1 25 signal_peptide
27 112 IG
212 308 IGc2
317 410 IG
413 507 TMD
589 924 TyrKc
589 926 Pkinase
121 205 IG
 

Kinexus Products

Click on entries below for direct links to relevant products from Kinexus for this protein kinase.
hiddentext
○ Mast/stem cell growth factor receptor protein-tyrosine Kit pan-specific antibody AB-NK241-1
○ Mast/stem cell growth factor receptor protein-tyrosine Kit pan-specific antibody AB-NK241-2
○ Mast/stem cell growth factor receptor protein-tyrosine Kit Y936 phosphosite-specific antibody AB-PK673
○ Mast/stem cell growth factor receptor protein-tyrosine Kit S821+Y823 phosphosite-specific antibody AB-PK674
○ Mast/stem cell growth factor receptor protein-tyrosine Kit (S38-D52, human) peptide - Powder PE-01AUS99
○ Mast/stem cell growth factor receptor protein-tyrosine Kit (S38-D52, human) peptide - Powder PE-01AUS99
○ Mast/stem cell growth factor receptor protein-tyrosine Kit (L119-L133, human) peptide - Powder PE-01AUT99
○ Mast/stem cell growth factor receptor protein-tyrosine Kit (L813-N819, human) peptide - Powder PE-01BFT99
○ Mast/stem cell growth factor receptor protein-tyrosine Kit (L813-N819, human) peptide - Powder PE-01BFU99
○ Mast/stem cell growth factor receptor protein-tyrosine Kit (N933-L939, human) pY936 phosphopeptide - Powder PE-04AGB95
○ Mast/stem cell growth factor receptor protein-tyrosine Kit (K818-G827, human) pS821+pY823 phosphopeptide - Powder PE-04ARM95
○ Mast/stem cell growth factor receptor protein-tyrosine Kit (N933-L939, human) pY936 phosphopeptide - Powder PE-04AZV00
 

Post-translation Modifications

For detailed information on phosphorylation of this kinase go to PhosphoNET
N-GlcNAcylated:
N130, N145, N283, N293, N300, N320, N352, N367, N463,N486.
Serine phosphorylated:

S215, S217, S240, S241, S279, S729, S741-, S746-, S821+, S891, S931, S937, S943, S959.
Threonine phosphorylated:

T232, T274, T354, T488, T718, T801.
Tyrosine phosphorylated:

Y362, Y494, Y547+, Y553+, Y568+, Y570+, Y578, Y609, Y703+, Y721, Y730, Y747, Y823+, Y900, Y936+.
Ubiquitinated:
K735, K738.
 

Distribution

Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:
% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:
  • adipose
    21

    913

    16

    1099

  • adrenal
    0.7

    30

    8

    18

  • bladder
    3

    143

    22

    188

  • brain
    32

    1362

    76

    2422

  • breast
    33

    1431

    14

    722

  • cervix
    3

    135

    50

    192

  • colon
    7

    293

    19

    391

  • heart
    12

    533

    53

    1177

  • intestine
    14

    590

    10

    386

  • kidney
    4

    164

    62

    121

  • liver
    0.8

    35

    32

    84

  • lung
    18

    756

    116

    742

  • lymphnode
    2

    81

    33

    86

  • ovary
    6

    261

    7

    229

  • pancreas
    0.9

    38

    22

    47

  • pituitary
    0.8

    33

    7

    33

  • prostate
    13

    573

    121

    3738

  • salivarygland
    4

    180

    28

    220

  • skeletalmuscle"
    0.9

    37

    66

    34

  • skin
    20

    874

    56

    718

  • spinalcord
    3

    141

    28

    151

  • spleen
    2

    68

    32

    87

  • stomach
    4

    183

    31

    283

  • testis
    2

    78

    26

    92

  • thymus
    1

    50

    30

    64

  • thyroid
    17

    744

    61

    854

  • tonsil
    2

    90

    36

    105

  • trachea
    3

    128

    26

    165

  • uterus
    3

    144

    27

    183

  • reticulocytes"
    3

    109

    14

    83

  • t-lymphocytes
    11

    462

    18

    359

  • b-lymphocytes
    100

    4276

    17

    10577

  • neutrophils
    5

    219

    48

    528

  • macrophages
    16

    666

    31

    690

  • sperm
    0.8

    33

    22

    32

 

Evolution

Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
  • tableheader
    100

    100

    100
  • tableheader
    90.3

    90.5

    100
  • tableheader
    98.4

    99.3

    98
  • tableheader
    -

    -

    90
  • tableheader
    -

    -

    90
  • tableheader
    40.5

    57.3

    89
  • tableheader
    -

    -

    -
  • tableheader
    82.3

    90

    83
  • tableheader
    40.2

    58.2

    83
  • tableheader
    -

    -

    -
  • tableheader
    66.5

    78

    -
  • tableheader
    66

    78.4

    67
  • tableheader
    56.3

    71.4

    59
  • tableheader
    48.6

    65.4

    51
  • tableheader
    46.3

    62.6

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
 

Regulation

Activation:
Activated by mast,stem cell growth factor (steel factor) binding, which induces dimerization and autophosphorylation. Phosphorylation of Tyr-568 induces interactions with APS, Cbl, SHP2, and Src.Phosphorylation of Tyr-900 induces interaction with Crk and PIK3C2A. Phosphorylation of Tyr-936 induces interaction with APS, Cbl, Grb2 and Grb7.
Inhibition:
Phosphorylation of Ser-741 and Ser-746 inhibits phosphotransferase activity.
Synthesis:
NA
Degradation:
NA
 

Kinections Map

Click here to download a PPT of the image below
 
Kinections GIF
 

Known Upstream Kinases

For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET predictions.
Based on in vitro and/or in vivo phosphorylation data

Kinase Short Name UniProt ID (Human) Phosphosite Location Phosphosite Sequence Effect of Phosphorylation
KIT P10721 Y703 DHAEAALYKNLLHSK +
PKCa P17252 S741 TKADKRRSVRIGSYI -
PKCa P17252 S746 RRSVRIGSYIERDVT -
SRC P12931 Y900 EHAPAEMYDIMKTCW ?
KIT P10721 Y936 SESTNHIYSNLANCS +
 

Known Downstream Substrates

For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET predictions.
Based on in vitro and/or in vivo phosphorylation data

Substrate Short Name UniProt ID (Human) Phosphosite Location Phosphosite Sequence Effect of Phosphorylation
Kit P10721 Y547 VMILTYKYLQKPMYE +
Kit P10721 Y553 KYLQKPMYEVQWKVV +
Kit P10721 Y568 EEINGNNYVYIDPTQ +
Kit P10721 Y570 INGNNYVYIDPTQLP +
Kit P10721 Y703 DHAEAALYKNLLHSK +
Kit P10721 Y721 CSDSTNEYMDMKPGV +
Kit P10721 Y823 DIKNDSNYVVKGNAR +
Kit P10721 Y936 SESTNHIYSNLANCS +
LAB Q9GZY6 Y110 RHGSEEAYIDPIAME
LAB Q9GZY6 Y118 IDPIAMEYYNWGRFS
 

Protein Kinase Specificity

Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites

Kinections GIF
Matrix Type:
Experimentally derived from alignment of 10 known protein substrate phosphosites and 100 peptides phosphorylated by recombinant Kit in vitro tested in-house by Kinexus.
Domain #:
1
 

Inhibitors

For further details on these inhibitors click on the Compound Name and enter it into DrugKiNET or click on the ID's
Based on in vitro and/or in vivo phosphorylation data
Compound Name KD, Ki or IC50 (nM) PubChem ID ChEMBL ID PubMed ID
Sunitinib Kd = 210 pM 5329102 535 18183025
Lestaurtinib Kd = 250 pM 126565 18183025
Cediranib Kd = 380 pM 9933475 491473 22037378
Axitinib KD = 490 pM 6450551 1289926 22037378
Dasatinib Kd = 620 pM 11153014 1421 18183025
Staurosporine Kd = 640 pM 5279 18183025
SU14813 Kd = 680 pM 10138259 1721885 18183025
Ki-20227 Kd = 690 pM 9869779 1908396 22037378
XL820 IC50 = 900 pM
Telatinib IC50 = 1 nM 9808844 18519779
Quizartinib Kd = 1.6 nM 24889392 576982 20925433
Tivozanib IC50 = 1.63 nM 9911830 16982756
Linifanib Kd = 1.7 nM 11485656 223360 18183025
PD173955 Kd = 1.8 nM 447077 386051 22037378
Dovitinib IC50 = 2 nM 57336746
Imatinib Ki = 2 nM 123596 941 22037378
CHEMBL504075 Kd = 2.2 nM 25218459 504075 19128971
Pazopanib Kd = 2.3 nM 10113978 477772 18183025
Foretinib Kd = 2.5 nM 42642645 1230609 22037378
Tandutinib Kd = 2.7 nM 3038522 124660 18183025
Motesanib Kd = 3.2 nM 11667893 572881 18183025
JNJ-28312141 Kd = 3.6 nM 22037378
2hiw EC50 = 4 nM 10062694 18077425
Cabozantinib IC50 = 4.6 nM 25102847 21926191
AST-487 Kd = 5 nM 11409972 574738 18183025
Vatalanib Kd = 5.1 nM 151194 101253 18183025
Nintedanib Kd = 5.7 nM 9809715 502835 22037378
Regorafenib IC50 = 7 nM 11167602 21170960
N-Benzoylstaurosporine Kd = 7.7 nM 56603681 608533 18183025
Barasertib Kd = 7.9 nM 16007391 215152 18183025
Masitinib Kd = 8.1 nM 10074640 22037378
AC1NS4N8 Kd < 10 nM 23649240 19035792
Amuvatinib IC50 = 10 nM 16058702
CHEMBL249097 Kd < 10 nM 25138012 249097 19035792
Sorafenib IC50 = 10 nM 216239 1336 18942827
SU11652 IC50 = 10 nM 24906267 13485 18077363
SureCN7018367 Kd < 10 nM 18792927 450519 19035792
Brivanib Kd = 12 nM 11234052 377300 22037378
Ponatinib IC50 = 12.5 nM 24826799 19878872
AZD1152 Kd = 17 nM 11497983 19320489
Nilotinib Kd = 29 nM 644241 255863 22037378
OSI-930 IC50 = 29 nM 53396311 21920748
CHEMBL1258913 IC50 = 35 nM 11847343 1258913 20817473
Semaxinib IC50 = 35 nM 5329098 276711 12477352
Ki8751 IC50 = 40 nM 11317348 178455 15743179
Hesperadin Kd < 50 nM 10142586 514409 19035792
MGCD-265 IC50 < 50 nM 24901704 18434145
SureCN5632345 Kd < 50 nM 44593646 515466 19035792
KW2449 Kd = 53 nM 11427553 1908397 22037378
Ki11502 IC50 = 86.81 nM 18309036
SureCN3590297 IC50 = 89 nM 24762205 1085511 20483608
Lenvatinib IC50 = 100 nM 9823820 17943726
Toceranib IC50 = 100 nM 5329106 13608 12091352
CHEMBL213618 IC50 = 110 nM 16043304 213618 16765046
NVP-TAE684 Kd = 110 nM 16038120 509032 22037378
CHEMBL511337 Kd = 111 nM 44588220 511337 19035792
ENMD 2076 IC50 = 120 nM 16041424 19320489
GSK690693 Kd = 130 nM 16725726 494089 22037378
TG101348 Kd = 130 nM 16722836 1287853 22037378
CHEMBL1240703 Kd = 140 nM 52945601 1240703 19654408
BML-275 IC50 > 150 nM 11524144 478629 22037377
Flt-3 Inhibitor III IC50 > 150 nM 11772958 22037377
JNJ-10198409 IC50 > 150 nM 9797370 120077 22037377
Lck Inhibitor IC50 > 150 nM 6603792 22037377
PDK1/Akt/Flt Dual Pathway Inhibitor IC50 > 150 nM 5113385 599894 22037377
Doramapimod Kd = 170 nM 156422 103667 18183025
RAF265 Kd = 170 nM 11656518 558752 18183025
PLX4720 Kd = 180 nM 24180719 1230020 22037378
Vandetanib Kd = 180 nM 3081361 24828 18183025
Saracatinib IC50 = 200 nM 10302451 217092 17064066
SureCN10063060 Ki = 200 nM 52936621 21391610
Tozasertib Kd = 240 nM 5494449 572878 18183025
VEGFR Kinase Inhibitor II IC50 = 240 nM 9797919 101683 12941313
AG-E-60384 IC50 > 250 nM 6419741 413188 22037377
AGL2043 IC50 > 250 nM 9817165 22037377
AT9283 IC50 = 250 nM 24905142
GSK-3 Inhibitor IX IC50 > 250 nM 5287844 409450 22037377
GSK-3 Inhibitor XIII IC50 > 250 nM 6419766 359482 22037377
KRN633 IC50 > 250 nM 406381 22037377
NU6140 IC50 > 250 nM 10202471 1802728 22037377
PKR Inhibitor; Negative Control IC50 > 250 nM 16760619 22037377
TWS119 IC50 > 250 nM 9549289 405759 22037377
VEGFR2 Kinase Inhibitor II IC50 > 250 nM 5329155 88606 22037377
VEGFR2 Kinase Inhibitor IV IC50 > 250 nM 5329468 92461 22037377
CP673451 IC50 = 252 nM 10158940 15705896
GTP-14564 IC50 = 300 nM 3385203 406375 18077363
L783277 IC50 = 303 nM 4592 499237
BX795 IC50 = 320 nM 10077147 577784 15772071
CHEMBL281820 IC50 = 343 nM 44275237 281820 12477352
CHEMBL377734 IC50 = 370 nM 11632737 377734 16789733
Ruboxistaurin Kd = 380 nM 153999 91829 15711537
BMS-690514 Kd < 400 nM 11349170 21531814
IKK-2 Inhibitor IV Kd < 400 nM 9903786 257167 19035792
Danusertib IC50 = 407 nM 21874004 402548 17125279
SureCN4139760 IC50 = 414 nM 25065806
Bosutinib Kd = 420 nM 5328940 288441 22037378
Apatinib IC50 = 429 nM 45139106 21443688
Flt-3 Inhibitor II IC50 = 500 nM 11601743 377193 22037377
IDR E804 IC50 = 500 nM 6419764 1802727 22037377
PDGF Receptor Tyrosine Kinase Inhibitor III IC50 = 500 nM 10907042 22037377
PKR Inhibitor IC50 = 500 nM 6490494 235641 22037377
ST078197 IC50 = 500 nM 1048845 210833 22037377
SU11274 IC50 = 500 nM 9549297 261641 22037377
SU4312 IC50 = 500 nM 6450842 328710 22037377
VEGFR2 Kinase Inhibitor I IC50 = 500 nM 6419834 86943 22037377
BIX02188 IC50 = 550 nM 23507698 18834865
JNJ-7706621 Kd = 590 nM 5330790 191003 18183025
Milciclib IC50 = 668 nM 16718576 564829 19603809
CHEMBL1651521 IC50 = 673 nM 53324451 1651521
BGJ398 IC50 = 750 nM 53235510 21936542
Crizotinib Kd = 800 nM 11626560 601719 22037378
Bafetinib IC50 = 840 nM 24853523 16105974
BX912 IC50 = 850 nM 11754511 15772071
BX320 IC50 = 890 nM 657138 573108 15772071
BMS-777607 IC50 < 900 nM 24794418 19260711
SGI-1776 IC50 < 900 nM 19734450
4557W IC50 > 1 µM 9843206 563845 22037377
AG1295 IC50 > 1 µM 2048 7724 22037377
AG1296 IC50 > 1 µM 2049 71191 22037377
Baricitinib IC50 > 1 µM 44205240 20363976
Bisindolylmaleimide IV IC50 > 1 µM 2399 266487 22037377
BML-277 IC50 > 1 µM 9969021 179583 22037377
Chelerythrine IC50 > 1 µM 72311 22037377
GSK-3 Inhibitor X IC50 > 1 µM 6538818 430226 22037377
Icotinib IC50 > 1 µM 22024915 22112293
K-252a; Nocardiopsis sp. IC50 > 1 µM 3813 281948 22037377
Kinome_714 IC50 > 1 µM 46886323 20346655
MK5108 IC50 > 1 µM 24748204 20053775
SB218078 IC50 > 1 µM 447446 289422 22037377
Silmitasertib IC50 > 1 µM 24748573 21174434
SNS314 IC50 > 1 µM 16047143 514582 18678489
SU6656 IC50 > 1 µM 5353978 605003 22037377
Syk Inhibitor IC50 > 1 µM 6419747 104279 22037377
TG003 IC50 > 1 µM 1893668 408982 22037377
TG101209 IC50 > 1 µM 16722832 17541402
WZ3146 Kd > 1 µM 44607360 20033049
WZ4002 Kd > 1 µM 44607530 20033049
BIX02188 IC50 = 1.1 µM 23507698 18834865
Enzastaurin Kd = 1.1 µM 176167 300138 22037378
CHEMBL248757 Ki = 1.119 µM 44444843 248757 17935989
JNK Inhibitor VIII Ki > 1.2 µM 11624601 210618 16759099
Kinome_3024 Ki > 1.2 µM 11539329 210963 16759099
Kinome_3027 Ki > 1.2 µM 11640926 378627 16759099
Kinome_3028 Ki > 1.2 µM 11590363 210928 16759099
CHEMBL1964275 Kd < 1.25 µM 57394915 1964275 19035792
SureCN373973 Kd < 1.25 µM 9818573 30678 19035792
Erlotinib Kd = 1.3 µM 176870 553 18183025
CHEMBL201511 IC50 = 1.9 µM 11530963 201511 20031417
PF-228 IC50 > 2 µM 11612883 17395594
PP121 IC50 < 2.5 µM 24905142 18849971
CHEMBL1784637 IC50 > 3 µM 46864270 1784637 21561767
PHA-665752 Kd = 3.2 µM 10461815 450786 22037378
SureCN4875304 IC50 > 3.5 µM 46871765 20472445
Canertinib Kd = 3.9 µM 156414 31965 18183025
JNJ-28871063 IC50 > 4 µM 17747413 17975007
Gefitinib Kd = 4.3 µM 123631 939 18183025
Alvocidib Kd = 4.6 µM 9910986 428690 18183025
 

Disease Linkage

General Disease Association:

Cancer, skin, bone, developmental, urological, and physiological disorders
Specific Diseases (Non-cancerous):

Urticaria; Dysphagia; Alveolar capillary dysplasia (ACD); Juvenile xanthogranuloma; Kimura disease; Mixed gonadal dysgenesis; Chronic cystitis
Comments:
Piebald Trait, Kit-Related is a rare genetic disease where there is the lack of pigment producing cells (melanocytes) in various areas around the skin and hair. Individuals suffering from Piebaldism (PBT) suffer from increased risks of skin cancer in the non-pigmented patches. In Piebald trait (PBT) a R796G mutation induced sensorineural deafness. PBT has correlated with the E583K, F584C, F584L, G601R, L565P, G664R, R791G, R796G, G812V, and T847P. Urticaria, often called hives, is characterized by an itchy skin rash. Dysphagia manifests with a difficulty of swallowing, and the disorder is related to muscular dystrophy and oculopharyngeal muscular dystrophy. Alveolar Capillary Dysplasia (ACD) is a rare respiratory and cardiovascular disease resulting in misalignment of pulmonary veins during development. Juvenile Xanthogranuloma is a rare form of non-langerhans cell histiocytes (tissue macrophages) and can result in anterior chamber anomaly, blindness, and conjunctivitis. Kimura Disease is an inflammation of sub-cutaneous nodes near the neck or head. It can also affect bone and kidney tissues. Mixed Gonadal Dysgenesis is a rare disorder that induces the asymetrical development of sex organs leading to mosaicism with regards to which sexual organs are prevalent. Chronic Cystitis is characterized by chronic inflammation of the bladder, but can also affect the prostate, testis, and pituitary gland.
 
Specific Cancer Types:
Piebald Trait, Kit-Related; Piebaldism (PBT); Gastrointestinal stromal tumours (GANT, GIST); Sarcomas; Mastocytosis; Acute myeloid leukemias (AML); Seminoma; Germ Cell tumours (GCT); Leiomyosarcomas; Thymic carcinomas; Urticaria Pigmentosa; Dysgerminomas; Uterine carcinosarcomas; Uterine sarcomas; Myelofibrosis (MYELOF); Teratomas; Carney Triad; Gonadoblastomas; Desmoid tumours; Hypereosinophilic syndrome (HES); Gastrointestinal stromal tumours, Familial; Cutaneous mastocytosis (CM); Gastrointestinal stromal tumours, somatic; Systemic mastocytosis (SMCD); Adenoid cystic carcinomas; Small cell carcinomas; Core binding factor acute myeloid leukemias (AML) (CBF-AML); Mast-Cell leukemias; Indolent systemic mastocytosis (ISM); Thymic epithelial tumours; Aggressive systemic mastocytosis (ASM); Polymorphous low-grade adenocarcinomas (PLGA); Liposarcomas; Small cell neuroendocrine carcinomas; Cutaneous leiomyosarcomas; Mast cell neoplasms; Extragonadal seminoma; Thymic epithelial neoplasm (TEN); Juvenile nasopharyngeal angiofibroma (JNA); Male germ cell tumours; Sinonasal undifferentiated carcinomas (SNUC); Fibrosarcomas of bone; Dermatofibrosarcoma protuberans (DFSP); Perineuriomas; Adenosarcomas; Embryonal sarcoma; Ewing's family of tumours; Microglandular adenosis; Malignant germ cell tumours; Mesenchymal cell neoplasm; Retroperitoneal leiomyosarcomas; Pancreatic mucinous cystadenomas; Reticular perineurioma; Sm-Ahnmd; Renal cell carcinomas (RCC); Aleukemic mast cell leukemias; Acute myeloblastic leukemias with maturation; Acute myeloid leukemias (AML) with T(8;21)(q22;q22) translocation; Acute myeloid leukemias (AML) with abnormal bone marrow eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22); Cutaneous mastocytoma; Isolated bone marrow mastocytosis; Pseudoxanthomatous diffuse cutaneous mastocytosis; Bullous diffuse cutaneous mastocytosis; Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease; Smouldering systemic mastocytosis; Nodular urticaria pigmentosa; Plaque-form urticaria pigmentosa; Typical urticaria pigmentosa; Lymphoadenopathic mastocytosis with eosinophilia; Classic mast cell leukemias
Comments:
KIT is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Gastrointestinal Stromal tumour (GANT, GIST) is a soft tissue sarcoma growing from the stomach, intestines, or rectum. Gastrointestinal stromal tumour (GIST) has correlated with deletion of residues 550-558, 551-555, 559-560, and 559 while common mutations in GIST are K550I, V559A, and V559D. Mastocytosis is a rare condition arising from an overproduction of mast cells in the body. Seminoma is a rare cancer of the germ-line, affecting the testis, lymph node, prostate, or mediastinum. Germ Cell tumours can affect the testis, ovaries, and lymph node tissues. Leiomyosarcoma is a rare sarcoma of the smooth muscle cells which can also affect the lung, liver, blood vessels, or other soft tissues. Thymic Carcinoma can affect the brain, thymus, and thyroid tissues and it is related to adenoid cystic carcinoma. Urticaria Pigmentosa is a very rare skin disorder where the accumulation of mast cells in the skin results in an overactive immune response, and hives. Dysgerminoma is a germ line tumour that typically only affects ovaries. Uterine Sarcoma is a rare malignant tumour of the connective tissue or smooth muscle in the uterus. Myelofibrosis (MYELOF), is characterized by the bone marrow being superimposed by scar tissue leading to anemia. Teratoma is a tumour that has multiple germ layers, and is often characterized as an encapsulated tumour. Carney Triad is related to the gastrointestinal stromal tumour and paranglioma disorders. Carney Triad is often characterized by mediastinal anomalies, and arrhythmia. The rare disorder Desmoid tumour is an abnormal growth of connective tissues which is highly aggressive (tissue invasion) but rarely spread (do not metastasize often). Hypereosinophilic Syndrome (HES) is a rare blood disorder with increased eosinophil levels and can affect lungs, kidneys, heart, and nervous system. Cutaneous Mastocytosis (CM) is a rare cancer with an expanded mastocyst population and can affect skin, bone, and bone marrow. Systemic Mastocytosis (SMCD) is a rare condition leading to expansion of the mastocyst population. Adenoid Cystic Carcinoma is a rare glandular cancer that can affect the salivary gland, lung, and breast. The rare condition Small Cell Carcinoma is a malignant tumour often arising from the lung. Merkel Cell Carcinoma is a form of skin cancer. Core Binding Factor Acute Myeloid Leukemia (CBF-AML) is a form of myeloid leukemia. In AML the R381A or E386A mutations partially impaired KitLG/SCF-induced autophosphorylation. In AML the I571A or L939A mutations can partly inhibit SH2B2/APS binding, but in conjunction the mutations will fully abrogate it. The S741A and S746A mutations in conjunction abrogated the inhibiting characteristic of PKC/PRKCA, allowing kinase phosphotransferase activity. A K623M mutation increased the strength AML bound MPDZ. Autophosphorylation at Tyr-900 can occur with a Y823F mutation in AML. The rare mastocyst cell carcinoma, Indolent Systemic Mastocytosis is related to systemic mastocytosis and mastocytosis. Thymic Epithelial tumour is a rare disease related to thymoma and breast cancer. Aggressive Systemic Mastocytosis (ASM) is a rare condition with symptoms including pulmonary infiltrates, respiratory failure, and bone fragility. The rare condition Polymorphous Low-Grade Adenocarcinoma (PLGA) is an asymptomatic, slow growing adenocarcinoma. Liposarcoma is a rare sarcoma stemming from fat tissue. Sarcomatoid Renal Cell Carcinoma is related to the spindle cell carcinoma and sarcoma conditions. Thymic Epithelial Neoplasm (TEN) is a cancer related to breast cancer and thymic epithelial tumours. TEN is a rare disease and can affect thymus, lung, and endothelial tissues. Juvenile Nasopharyngeal Angiofibroma (JNA) is a rare condition related to familial adenomatous polyposis and nasopharyngitis. Sinonasal Undifferentiated Carcinoma is a rare carcinoma developing from the sinus, and can affect skin and liver. Dermatofibrosarcoma Protuberans (DFSP) is a rare sarcoma that can also affect breast and lung tissues. Perineurioma is rare and relates to the granular cell tumour and neurofibromatosis disorders. Embryonal Sarcoma is a rare sarcoma, is related to rhabdomyosarcoma, and it can affect lung, liver, and kidney tissues. Ewing's Family of tumours is a rare cancer disease that is similar to medullablastoma and cerebral primitive neuroectodermal tumour. Malignant Germ Cell tumour is related to the germ cell tumours and gonadoblastoma disorders. Malignant Germ Cell tumour can affect ovaries, testis, and lymph nodes. The rare condition Renal Cell Carcinoma (RCC) is a form of kidney cancer arising from the proximal renal tube. Aleukemic Mast Cell Leukemia has a relation to the mast-cell leukemia and leukemia disorders. Acute Myeloblastic Leukemia with Maturation is a form of AML and affects myeloid tissue. Acute Myeloid Leukemia with T(8;21)(q22;q22) Translocation has a relation to the juvenille myelomonocytic leukemia and myeloid sarcoma disorders. Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) can affect myeloid, bone marrow, and bone tissues. It is a rare cancer that has a relation to myeloid sarcoma and acute myeloid leukemia disorders. Cutaneous Mastocytoma is characterized by hot/cold flashes, migraines, and acute abdominal pain. Isolated Bone Marrow Mastocytosis can affect bone marrow, bone, and skin. Pseudoxanthomatous Diffuse Cutaneous Mastocytosis is characterized by dermal infiltration, vesicle detachment, and mastocytosis. Bullous Diffuse Cutaneous Mastocytosis can be characterized by symptoms including erythematous lesions, and vesicle detachment. Systemic Mastocytosis with an Associated Clonal Hematologic Non-Mast Cell Lineage Disease is a rare disease characterized by symptoms including hypereosinophilia, acute leukemia, and myeloproliferative syndrome. Smouldering Systemic Mastocytosis is a rare condition affecting lymph node tissues and which has a relation to systemic mastocytosis and mastocytosis. The rare disorder Nodular Urticaria Pigmentosa affects skin, and has a relation to urticaria pigmentosa, and uticaria. Typical Urticaria Pigmentosa is a rare condition affecting skin. Acute Myeloid Leukemia (AML) is a rare blood cancer disease which will displace healthy blood cells and can lead to fever, shortness of breath, fatigue, and easy bruising.
 
Gene Expression in Cancers:

TranscriptoNET (www.transcriptonet.ca) analysis with mRNA expression data retrieved from the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database, which was normalized against 60 abundantly and commonly found proteins, indicated altered expression for this protein kinase as shown here as the percent change from normal tissue controls (%CFC) as supported with the Student T-test in the following types of human cancers: Brain oligodendrogliomas (%CFC= -51, p<0.006); Breast epithelial carcinomas (%CFC= -89, p<0.021); Breast epithelial cell carcinomas (%CFC= -60, p<0.0001); Breast epithelial hyperplastic enlarged lobular units (HELU) (%CFC= -86, p<0.002); Breast non-basal-like cancer (BLC) (%CFC= -50, p<0.0001); Breast stromal cell carcinomas (%CFC= -48, p<0.002); Gastric cancer (%CFC= -50, p<0.007); Malignant pleural mesotheliomas (MPM) tumours (%CFC= -73, p<0.008); Papillary thyroid carcinomas (PTC) (%CFC= -73, p<0.001); Pituitary adenomas (ACTH-secreting) (%CFC= -90); Skin melanomas - malignant (%CFC= +148, p<0.0001); Skin squamous cell carcinomas (%CFC= -63, p<0.008); Uterine leiomyomas from fibroids (%CFC= -60, p<0.042); and Vulvar intraepithelial neoplasia (%CFC= -50, p<0.003). The COSMIC website notes an up-regulated expression score for KIT in diverse human cancers of 326, which is 0.7-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 0 for this protein kinase in human cancers was 100% lower than the average score of 60 for the human protein kinases.
Mutagenesis Experiments:

Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:

Percent mutation rates per 100 amino acids length in human cancers: 1.31 % in 57908 diverse cancer specimens. This rate is 17.5-fold higher than the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:

Highest percent mutation rates per 100 amino acids length in human cancers: 4.84 % in 9010 soft tissue cancers tested; 1.81 % in 12309 haematopoietic and lymphoid cancers tested; 0.94 % in 1854 large intestine cancers tested; 0.74 % in 208 thyroid cancers tested; 0.7 % in 5119 skin cancers tested; 0.23 % in 537 bone cancers tested; 0.2 % in 890 stomach cancers tested; 0.19 % in 1365 ovary cancers tested; 0.15 % in 1598 kidney cancers tested; 0.15 % in 1300 liver cancers tested; 0.12 % in 3399 lung cancers tested; 0.11 % in 2347 breast cancers tested; 0.08 % in 1355 pancreas cancers tested; 0.06 % in 2529 central nervous system cancers tested.
Frequency of Mutated Sites:

Most frequent mutations with the number of reports indicated in brackets: D816V (1486); D816? (195); V559D (230); V560D (172); L576P (186); W557R (118); D816Y (54); V559A (53).
Comments:
Over a hundred complex mutations and over 500 deletions mutations are concentration between amino acid residues Y553 to K558, which is located just before the protein kinase catalytic domain. The Y503 site has over 380 insertions mutations.
 
COSMIC Entry:
KIT
OMIM Entry:
164920
  • Home
  • Top of Page
Copyright 2019 Kinexus BioInformatics Corporation